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ARFID

:   avoidant restrictive food intake disorder

DSM‐5

:   *Diagnostic and Statistical Manual of Mental Disorders* fifth edition

HRQOL

:   health related quality of life

PedsQL

:   Pediatric Quality of Life Inventory

TAPQOL

:   TNO‐AZL Preschool Children Quality of Life

1. INTRODUCTION {#eat23037-sec-0005}
===============

The diagnosis "avoidant restrictive food intake disorder (ARFID)" was introduced in the *Diagnostic and Statistical Manual of Mental Disorders* fifth edition (DSM‐5) in 2013. It extended and replaced the formerly used DSM‐IV diagnosis "feeding disorder of infancy and early childhood" (American Psychiatric Association & DSM‐5 Task Force, [2013](#eat23037-bib-0001){ref-type="ref"}; Bryant‐Waugh, [2013](#eat23037-bib-0004){ref-type="ref"}; Kerzner et al., [2015](#eat23037-bib-0025){ref-type="ref"}). ARFID describes an eating/feeding disturbance (e.g., lack of interest in eating/food; avoidance based on the sensory characteristics of food; concern about aversive consequences of eating) as manifested by persistent failure to meet appropriate nutritional/energy needs associated with ≥1 of the following: significant weight loss/failure to achieve expected weight gain/faltering growth in children, significant nutritional deficiency, dependence on enteral feeding/oral nutritional supplements, or a marked interference with psychosocial functioning (American Psychiatric Association & DSM‐5 Task Force, [2013](#eat23037-bib-0001){ref-type="ref"}).

ARFID is a common clinical entity, with a point prevalence rate of 3.2% in a general pediatric population (Kurz, van Dyck, Dremmel, Munsch, & Hilbert, [2015](#eat23037-bib-0028){ref-type="ref"}). Earlier studies found ARFID patients to be younger, the proportion of males to be higher, and to be more commonly diagnosed with comorbid psychiatric and/or medical symptoms compared to other DSM‐5 eating disorders (Norris, Spettigue, & Katzman, [2016](#eat23037-bib-0034){ref-type="ref"}). However, ARFID is a heterogeneous clinical group including all age groups from young children to adults. In a study including ARFID patients aged 10--18 years, 30% were male, 55% had comorbid medical conditions and 58% anxiety disorders. This was significantly more common compared to children with other DSM‐5 eating disorders (Fisher et al., [2014](#eat23037-bib-0017){ref-type="ref"}). While more is known about general feeding disorders in younger patients, relatively few studies have been published describing clinical features of ARFID in children younger than 10 years of age.

Feeding problems caused by ARFID can lead to poor nutrition, which can result in malnourishment, faltering in growth and nutritional deficiencies (Kerzner, [2009](#eat23037-bib-0024){ref-type="ref"}; Silverman, [2010](#eat23037-bib-0038){ref-type="ref"}). For this reason, dietary supplements or tube feeding can be administered (Gottrand & Sullivan, [2010](#eat23037-bib-0018){ref-type="ref"}). ARFID may have an impact on the child\'s life due to hospital visits, feeding tube replacements, feeding therapy, stress during mealtimes and related parent--child interaction problems. A method that is commonly used to assess the impact of a disorder on a child\'s life is evaluating the health related quality of life (HRQOL) (Haverman et al., [2012](#eat23037-bib-0020){ref-type="ref"}), which incorporates measures of physical symptoms, functional status, and disease impact on psychological and social functioning (Eiser & Morse, [2001a](#eat23037-bib-0012){ref-type="ref"}; Haverman et al., [2012](#eat23037-bib-0020){ref-type="ref"}; Linscheid, [2006](#eat23037-bib-0030){ref-type="ref"}; Payot & Barrington, [2011](#eat23037-bib-0036){ref-type="ref"}). A study measuring HRQOL in adults with ARFID found lower mental HRQOL scores compared to the general population (Hay et al., [2017](#eat23037-bib-0022){ref-type="ref"}). To the best of our knowledge, however, the HRQOL of children with ARFID, and in particular, in those who are tube‐dependent, has not yet been studied. It is known, however, that tube feeding can result in loss of appetite, food aversion, delayed transition to oral feeding, and impact the psychosocial functioning of the child and it\'s family (Benoit, Wang, & Zlotkin, [2000](#eat23037-bib-0003){ref-type="ref"}; Hartdorff et al., [2015](#eat23037-bib-0019){ref-type="ref"}; Krom et al., [2018](#eat23037-bib-0027){ref-type="ref"}; Krom, de Winter, & Kindermann, [2017](#eat23037-bib-0026){ref-type="ref"}; Wilken, Bartmann, Dovey, & Bagci, [2018](#eat23037-bib-0039){ref-type="ref"}).

Therefore, the primary aim of our study is to compare the HRQOL of infants and children with ARFID to both healthy and chronically ill controls. The secondary aim is to compare the HRQOL of children with ARFID receiving tube feeding to those without tube feeding.

2. METHOD {#eat23037-sec-0006}
=========

2.1. Participants and procedure {#eat23037-sec-0007}
-------------------------------

A cross‐sectional study was conducted at the Diagnostic Center for Feeding Problems in the Emma Children\'s Hospital/Amsterdam UMC (tertiary care) in Amsterdam, the Netherlands, between September 12, 2014 and July 1, 2016. Patients aged 0--10 years were referred by pediatricians or general practitioners because of feeding difficulties, and evaluated by our multidisciplinary feeding team, consisting of a pediatric gastroenterologist, dietician, psychologist, and speech language pathologist.

Prior to the scheduled outpatient multidisciplinary consultation, a letter with information about the aims and procedure of the study was sent to the parents of the patients. Thereafter, the parents were called to check whether they received the letter and to give them the opportunity to ask questions. After parental consent, a user name and password, enabling to login on our web‐based method ([www.hetklikt.nu](http://www.hetklikt.nu); Haverman et al., [2014](#eat23037-bib-0021){ref-type="ref"}) were sent by e‐mail, and the appropriate questionnaires (depending on child\'s age) for assessing socio‐demographics and HRQOL (see paragraphs "Socio‐demographics" and "HRQOL") were automatically selected.

Patients fulfilling the DSM‐5 criteria for ARFID were considered eligible for participation and were included in the analyses for the present study. Following the DSM‐5 criteria, these children suffer from a feeding disturbance. This is evident from the failure to meet nutritional and/or energy needs, resulting in faltering growth, poor weight gain, weight loss, nutritional deficiencies, tube feeding or nutritional supplement dependence, and/or problems in psychosocial functioning. If the feeding disturbance is better explained by a medical condition, another mental disorder, anorexia or bulimia nervosa, body shape/weight related, lack of food, or cultural/religious practices, children are excluded from the diagnosis. If, however, the feeding disturbance occurs in the context of another condition, and is more severe than general, the children may be diagnosed with ARFID (American Psychiatric Association & DSM‐5 Task Force, [2013](#eat23037-bib-0001){ref-type="ref"}). Eligibility was checked retrospectively by a research physician, who also works as a medical doctor diagnosing and treating children with feeding disorders in our tertiary center. Extensive chart reports of the multidisciplinary team members were consulted, before analyzing the data (see paragraph "Medical and paramedical data").

Eligible patients of whom the parents completed the questionnaires were defined as participants, and those of whom the parents did not, were defined as nonparticipants.

The Committee for Medical Ethics at the Academic Medical Center in Amsterdam, the Netherlands confirmed that the Medical Research Involving Human Subjects Act did not apply to our study.

2.2. Measures {#eat23037-sec-0008}
-------------

### 2.2.1. Socio‐demographics {#eat23037-sec-0009}

Online baseline questionnaires were completed by the fathers or mothers of the participating patients to obtain information regarding both patients and parents. Incomplete socio‐demographic data were completed during psychological consultation.

### 2.2.2. Medical and paramedical data {#eat23037-sec-0010}

Medical and paramedical data of both the participants and nonparticipants were collected during the standardized consultations by our multidisciplinary team.

The pediatric gastroenterologist assessed medical data with respect to history (age, sex, gestational age, birth weight, and age onset of the feeding problems), underlying diseases (or alarm symptoms for underlying diseases such as oral motor skill difficulties, dysphagia, odynophagia, vomiting, recurrent ear nose throat or airway disease, abnormal defecation, and neurological symptoms) and medication. At physical examination the pediatric gastroenterologist checked for the general condition and abnormalities, which could indicate underlying diseases. The speech language pathologist collected data concerning feeding skills and speech language development. The dietician obtained data according to type of feeding (orally of by tube) and nutritional intake including dietary supplements. The psychologist assessed social--emotional and psychosocial functioning, development, behavioral problems, traumatic experiences related to feeding, parental coping with feeding problems, and the psychological history of parents.

During consultation, weight and height were assessed by a digital scale and height chart. TNO growth‐charts for height for age, weight for age and weight for height (The Netherlands, 2010) were available for measuring standard deviation scores. *SD* scores for height and weight were corrected when the gestational age was \<37 weeks until a patients\' calendar age of 24 months. Disease specific secondary reference curves for *SD* scores for height (for patients with Down syndrome, Noonan syndrome, and Silver‐Russell syndrome) and weight (Down syndrome) were used as appropriate.

2.3. Definitions {#eat23037-sec-0011}
----------------

We classified medical diagnoses into categories used by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10 Version: 2016; World Health Organization \[WHO\], [2016](#eat23037-bib-0040){ref-type="ref"}).

Prematurity was defined as gestational age \< 37 weeks. Small for gestational age was defined as birth weight \< p10.

We used following definitions for the DSM‐5 criteria "Significant weight loss or failure to achieve expected weight gain or faltering growth" (American Psychiatric Association & DSM‐5 Task Force, [2013](#eat23037-bib-0001){ref-type="ref"}): Acute malnourishment was defined as weight for age \< −2 *SD* in children \<1 year, and weight for height \< −2 *SD* in children \>1 year, or a faltering in growth \>1 *SD* within 3 months on TNO growth charts. Chronic malnourishment was defined as height for age \<−2 *SD* for all age groups. Growth delay was defined as deflection of \>1 *SD* in 3 months in all age groups, a deflection of 0.5--1 *SD* per year in children aged \<4 and of 0.25 *SD*/year in children aged ≥4 years (Joosten, [2012](#eat23037-bib-0023){ref-type="ref"}).

Demographics of the participants were compared to the nonparticipants to check for sample representativeness.

### 2.3.1. HRQOL {#eat23037-sec-0012}

The TNO‐AZL Preschool Children Quality of Life (TAPQOL) and Pediatric Quality of Life Inventory (PedsQL) questionnaires were completed by parents of the patients to assess HRQOL. The TAPQOL and PedsQL scores were computed according to the manual, and subscales were constructed. Cronbach\'s alpha was calculated to assess the internal consistency of the questionnaires. Cronbach\'s alpha was considered low \<0.50, moderate 0.50--0.70, and good \>0.70 (Cronbach, [1951](#eat23037-bib-0007){ref-type="ref"}; Field, [2009](#eat23037-bib-0016){ref-type="ref"}).

### 2.3.2. TAPQOL {#eat23037-sec-0013}

We used the TAPQOL, a reliable and valid instrument for measuring parents\' perception of HRQOL in preschool children (aged 0--5 years) (Fekkes et al., [2000](#eat23037-bib-0015){ref-type="ref"}). The TAPQOL is a generic, multidimensional HRQOL questionnaire based on 43 proxy reported questions. It assesses the child\'s functioning in the past 4 weeks on 12 multi‐item scales: Stomach (three items), skin (three items), lungs (three items), sleeping (four items), appetite (three items), motor functioning (four items), positive mood (three items), anxiety (three items), liveliness (three items), problem behavior (seven items), social functioning (three items), and communication (four items). Higher scores on these subscales indicate higher HRQOL. The subscales motor functioning, social functioning, and communication only apply for children older than 18 months. Dutch norm data for healthy and chronically ill patients were used as control groups. These data were retrieved from a Dutch general population of children 1--5 years of age visiting six well‐baby clinics, and were described previously (2000) (Fekkes et al., [2000](#eat23037-bib-0015){ref-type="ref"}).

Besides the lung subscale (0.510), Cronbach\'s alpha in our sample was between 0.714 and 0.929, indicating a good internal consistency for the TAPQOL.

### 2.3.3. PedsQL {#eat23037-sec-0014}

The PedsQL was used to assess the HRQOL for patients aged 6--7 years (by proxy version) and 8--10 years (self‐report version). The PedsQL is a 23‐item questionnaire covering four subscales of the child\'s functioning in the past week: Physical (eight items), emotional (five items), social (five items), and school functioning (five items). Higher scores on these subscales indicate higher HRQOL. The by proxy version is a parallel version of the self‐report version. The person tense (first at the self‐report and third at the by proxy version) and language (age appropriate) were different. Dutch norm data for healthy and chronically ill children from the general population, retrieved from urban and suburban elementary schools in Amsterdam, described previously (2009), were used as control groups (Engelen, Haentjens, Detmar, Koopman, & Grootenhuis, [2009](#eat23037-bib-0014){ref-type="ref"}).

Cronbach\'s alpha for the PedsQL (6--7) in our population indicated a low internal consistency for the psychosocial health (0.434), and school functioning (0.331) subscales. The other subscales showed a good internal consistency (Cronbach\'s alpha 0.737--0.866).

2.4. Statistical analysis {#eat23037-sec-0015}
-------------------------

The Statistical Package for Social Science (IBM SPSS Statistics) version 23 was used to manage and analyze the data. To determine the prevalence of ARFID in our population we generated a bootstrapped confidence interval (Bca CI95%) based on 1,000 samples. Normality was tested through the Shapiro--Wilk test in addition to eyeballing. Differences between participants and nonparticipants were analyzed using T‐tests for normally distributed variables (*SD* scores for height, weight, and weight for height), Mann--Whitney U tests for not normally distributed variables (age, age of onset feeding disorder, gestational age, and birth weight), and Fischer Exact tests for binary variables (gender, underlying diseases, medication, and tube feeding). The HRQOL subscales of the children with ARFID were compared to both a healthy and a chronically ill Dutch norm population, and within the largest age group (0--5 years), the HRQOL of children with ARFID receiving tube feeding were compared to those without tube feeding using Mann--Whitney U tests.

Effect sizes (*r*) were measured by using the following formula: *r* = Z/(√*N*), where *Z* is the *Z*‐value and *N* is the total number of samples. The standard values for small, medium, and large effect sizes were 0.1, 0.3, and 0.5, respectively (Field, [2009](#eat23037-bib-0016){ref-type="ref"}). Due to multiple testing we defined *P* \< .01 as statistically significant.

3. RESULTS {#eat23037-sec-0016}
==========

A total of 100 patients were evaluated by our multidisciplinary team between September 12, 2014 and July 1, 2016. The prevalence of new patients fulfilling the ARFID criteria was 64% (95% Bs CI 54.1--73.3). The most important criteria for ARFID in these patients were the failure of meeting nutritional and/or energy needs, shown by tube feeding (62.5%) or supplement (10.9%) dependence, growth faltering/limited weight gain/weight loss (9.4%), nutritional deficiencies (3.1%), or problems in psychosocial functioning (14.1%). Seventy‐five percent of these eligible patients participated in the study (see Figure [1](#eat23037-fig-0001){ref-type="fig"}).

![Flowchart inclusion, participants, and nonparticipants](EAT-52-410-g001){#eat23037-fig-0001}

3.1. Socio‐demographic and medical characteristics {#eat23037-sec-0018}
--------------------------------------------------

The median age (corrected for prematurity) of the ARFID patients was 1.85 years (IQR 1.19--4.61), and 64.1% were females. No significant differences for baseline patient\'s characteristics were found between participants and nonparticipants (Table [1](#eat23037-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics of the patients

                                                                         Participants (*n* = 48)                          Nonparticipants(*n* = 16)                         
  ---------------------------------------------------------------------- ------------------------- ---------------------- --------------------------- --------------------- -------------------------------------------------
  *History*                                                                                                                                                                 
  Age (years)                                                            48                        1.84 (1.19--4.61)      16                          2.32 (0.85--2.58)     1.000
  Gestational age (weeks)                                                45^3^                     38.14 (36.00--39.43)   14^2^                       37.5 (36.25--38.72)   0.748
  Birth weight (grams)                                                   43^5^                     2,700 (1895--3,305)    13^3^                       2,760 (2413--3,017)   0.966
  Age of onset feeding disorder (months)                                 46^2^                     0 (0--1.75)            15^1^                       0 (0--2)              0.545
                                                                         ***N***                   **Mean (*SD*)**        ***N***                     **Mean (*SD*)**       ***P*** [b](#eat23037-note-0004){ref-type="fn"}
  *Physical examination*                                                                                                                                                    
  Height (*SD*)[c](#eat23037-note-0005){ref-type="fn"}                   46^1^                     −0.78 (1.24)           16                          −1.07 (1.49)          0.460
  Weight (*SD*)[c](#eat23037-note-0005){ref-type="fn"}                   46^1^                     −1.31 (1.18)           16                          −1.45 (1.61)          0.726
  Weight for height (*SD*)                                               46^1^                     −0.90 (1.11)           16                          −0.85 (1.13)          0.879
                                                                         ***N***                   **%**                  ***N***                     **%**                 ***P*** [d](#eat23037-note-0006){ref-type="fn"}
  Sex (female)                                                           31                        64.6                   10                          62.5                  1.000
  *History*                                                                                                                                                                 
  Underlying diseases                                                    43                        89.6                   14                          87.5                  1.000
  Prematurity                                                            17^3^                     35.4                   6^2^                        42.9                  0.762
  Small for gestational age                                              9^8^                      18.8                   2^3^                        15.4                  0.711
  Diseases of the circulatory system                                     8^1^                      16.7                   5                           31.3                  0.286
  Diseases of the respiratory system/Infections                          21                        43.8                   3                           18.8                  0.084
  Congenital malformations, deformations and chromosomal abnormalities   11                        22.9                   3                           18.8                  1.000
  Diseases of the digestive system                                       21                        43.8                   9                           56.3                  0.405
  Endocrine, nutritional and metabolic diseases                          1                         2.1                    0                           0                     1.000
  Diseases of the skin and subcutaneous tissue                           5^3^                      10.4                   2                           12.5                  1.000
  Mental and behavioral disorders                                        7                         14.6                   0                           0                     0.178
  Other diseases                                                         28                        58.3                   12                          75                    0.372
  Medication                                                             36                        75.0                   8                           50                    0.117
  Tube feeding                                                           28                        58.3                   10                          62.5                  1.000

^1^One missing data; ^2^Two missing data; ^3^ Three missing data; ^4^ Four missing data; ^5^Five missing data; ^8^Eight missing data; ^9^Nine missing data.

Significant difference (*P* \< .01).

Mann--Whitney *U* tests.

*T*‐tests.

*SD* scores were corrected when gestational age was \<37 weeks until a patients\' calendar age of 24 months. Disease specific secondary reference curves for *SD* scores for height (for patients with Down syndrome, Noonan syndrome, and Silver--Russell syndrome) and weight (Down syndrome) were used as appropriate (TNO growth‐charts, The Netherlands, 2010).

Fischer Exact tests.

Baseline characteristics of the parents of 48 participants and 16 nonparticipants are shown in Supporting Information Table [S1](#eat23037-supitem-0001){ref-type="supplementary-material"}.

3.2. HRQOL--TAPQOL {#eat23037-sec-0019}
------------------

TAPQOL scores for HRQOL were available for 37 ARFID patients aged 0--5 years (see Table [2](#eat23037-tbl-0002){ref-type="table"}). The age of patients included in this study did not differ significantly with the norm group (*P* = .046).

###### 

HRQOL in children with ARFID compared to Dutch norm groups

  TAPQOL(0--5 years)   Children with ARFED   Reference group healthy population   Reference group chronically ill children                                                                                                                                                                          
  -------------------- --------------------- ------------------------------------ ------------------------------------------ ----- -------- ----------------- ---------------------------------------------- ------ ---- --------- ----------------- ---------------------------------------------- -------
  Sleeping             37                    81.25                                50.00--93.75                               241   87.50    75.00--100,00     .0181                                          −.14   79   81.25     75.00--100.00     .163                                           −.078
  Appetite             37                    75.00                                50.00--75.00                               240   83.33    75.00--100.00     .0001                                          −.42   79   83.33     75.00--91.67      .000[\*](#eat23037-note-0007){ref-type="fn"}   −.275
  Lungs                37                    83.33                                *66.67--*100.00                            241   100.00   100.00--100.00    .000[\*](#eat23037-note-0007){ref-type="fn"}   −.42   79   100.00    *66.61--*100.00   .297                                           −.059
  Stomach              37                    *66.67*                              50--100                                    239   100.00   83.33--100.00     .000[\*](#eat23037-note-0007){ref-type="fn"}   −.34   79   100.00    83.33--100.00     .000[\*](#eat23037-note-0007){ref-type="fn"}   −.236
  Skin                 37                    91.76                                83.33--100                                 241   100.00   91.67--100.00     .440                                           −.05   78   91.67     83.33--100.00     .418                                           −.045
  Motor functioning    21                    100.00                               78.125--100.00                             202   100.00   100.00--100.00    .000[\*](#eat23037-note-0007){ref-type="fn"}   −.30   71   100.00    100.00--100.00    .000[\*](#eat23037-note-0007){ref-type="fn"}   −.212
  Social functioning   21                    100.00                               83.33--100.00                              205   100.00   83.33--100.00     .452                                           −.05   71   100.00    83.33--100.00     .249                                           −.070
  Problem behavior     37                    78.57                                64.29--85.71                               241   71.43    57.14--78.57      .002[\*](#eat23037-note-0007){ref-type="fn"}   −.19   79   71.43     57.14--78.57      .007[\*](#eat23037-note-0007){ref-type="fn"}   −.150
  Communication        21                    93.75                                81.25--100.00                              201   93.75    87.50--100.00     .622                                           −.03   68   93.75     87.50--100.00     .588                                           −.033
  Anxiety              37                    *66.67*                              50.00--100.00                              241   83.33    *66.61--*100.00   .102                                           −.10   79   *66.67*   *66.61--*100.00   .434                                           −.044
  Positive mood        37                    100.00                               100.00--100.00                             241   100.00   100.00--100.00    .006[\*](#eat23037-note-0007){ref-type="fn"}   −.16   79   100.00    100.00--100.00    .079                                           −.107
  Liveliness           37                    100.00                               83.33--100.00                              240   100.00   100.00--100.00    .000[\*](#eat23037-note-0007){ref-type="fn"}   −.24   79   100.00    100.00--100.00    .004[\*](#eat23037-note-0007){ref-type="fn"}   −.151

*P* \< .05.

*P* \< .01.

*Note*. Higher scores represent higher quality of life (scores 0--100).

The HRQOL of patients with ARFID was significantly lower in six of 12 subscales (appetite, lungs, stomach, motor functioning, positive mood, and liveliness) compared to healthy controls (*P* \< .01). The subscale problem behavior was significantly higher compared to the healthy controls (*P* \< .01).

The HRQOL of patients with ARFID was significantly lower in four of 12 subscales (appetite, stomach, motor functioning, and liveliness), and higher in the subscale problem behavior compared to children with other chronic health conditions (*P* \< .01).

3.3. HRQOL---PedsQL {#eat23037-sec-0020}
-------------------

The HRQOL of patients aged 6--7 years with ARFID (*n* = 9) was significantly lower in three of six subscales (total score, psychosocial health, and school functioning) compared to healthy controls (*P* \< .01). Comparing the ARFID patients to chronically ill children, no significant differences were found in any scale (see Table [3](#eat23037-tbl-0003){ref-type="table"}).

###### 

HRQOL of ARFID patients (aged 6--7 and 8--10 years) compared to healthy and chronically ill controls

  PEDSQOL                 Children with ARHD   Reference group healthy population   Reference group chronically ill children                                                                                                                                                                           
  ----------------------- -------------------- ------------------------------------ ------------------------------------------ ----- ------- ---------------- ------------------------------------------------ -------- ---- ------- ---------------- ------------------------------------------------ -------
  *6--7 year old*                                                                                                                                                                                                                                                                                      
  Total score             9                    71.74                                69.02 -- 78.80                             61    88.04   81.52 -- 91.85   .000[\*](#eat23037-note-0010){ref-type="fn"}     −.4011   11   80.34   73.91 -- 86.96   .09                                              −.383
  Physical health         9                    75.00                                68.75 -- 89.06                             61    90.63   84.38 -- 96.88   .016[\*\*](#eat23037-note-0011){ref-type="fn"}   −.28     11   81.25   71.88 -- 93.75   .42                                              −.188
  Psychosocial health     9                    71.67                                65.00 -- 75.83                             61    85      79.17‐ 91.67     .000[\*](#eat23037-note-0010){ref-type="fn"}     −.415    11   83.33   73.33 -- 86.67   .048                                             −.443
  Emotional functioning   9                    65.00                                62.50 -- 77.50                             61    80      70--90           .033[\*\*](#eat23037-note-0011){ref-type="fn"}   −.2527   11   80      60--85           .506                                             −.156
  Social functioning      9                    75.00                                70.00 -- 96.25                             61    95      80--100          .080                                             −.21     11   85      75--90           0.56                                             −.137
  School functioning      9                    65.00                                55.00--75.00                               61    85      79.17‐ 91.67     .000[\*](#eat23037-note-0010){ref-type="fn"}     −.4042   11   80      70--90           .047[\*\*](#eat23037-note-0011){ref-type="fn"}   −.445
  *8--12 years old*                                                                                                                                                                                                                                                                                    
  Total score             2                    65.22                                                                           192   82.61   77.17--89.13     .357                                             −.0719   26   79.89   73.37--88.59     .516                                             −.135
  Physical health         2                    60.94                                                                           192   87.5    81.25 -- 90.63   .968                                             −.0027   26   84.38   75--88.28        .966                                             −.017
  Psychosocial health     2                    67.50                                                                           192   81.67   73.33            .126                                             −.11     26   79.17   71.25 -- 88.33   .167                                             −.279
  Emotional functioning   2                    70.00                                                                           192   75      66.25 -- 85.00   .67                                              −.0315   26   77.5    70--90           .622                                             −.102
  Social functioning      2                    80.00                                                                           192   90      80--95           .213                                             −.092    26   82.5    78.75 -- 91.25   .63                                              −.121
  School functioning      2                    52.50                                                                           192   80      70--85           .006[\*](#eat23037-note-0010){ref-type="fn"}     −.16     26   75      68.75--85        .021[\*\*](#eat23037-note-0011){ref-type="fn"}   −.401

*P* \< .01.

*P* \< .05.

*Note*. higher scores represent higher HRQOL (scores 0--100).

The HRQOL of patients with ARFID aged 8--10 was lower in the subscale school functioning compared to healthy controls (*P* \< .01; see Table [3](#eat23037-tbl-0003){ref-type="table"}). Comparing ARFID patients to chronically ill children, no significant differences were found in any scale.

Due to small numbers for the PedsQL in both age groups (6--7 and 8--10 years), and a low internal consistency in some of the subscales (see Method section), these results are explorative.

3.4. HRQOL of ARFID patients with and without tube feeding {#eat23037-sec-0021}
----------------------------------------------------------

In total, 28 participating ARFID patients received tube feeding by nasogastric tube (*n* = 21), percutaneous endoscopic gastrostomy (*n* = 6), or button (*n* = 1). The tube feeding started at a median age of 1 (IQR 0‐6) month. Twenty‐seven of these patients were in the age group 0--5 years. The TAPQOL scores of these 27 patients were compared with patients in the same age group not receiving tube feeding (*n* = 10).

The HRQOL of ARFID patients receiving tube feeding did not differ significantly compared to ARFID patients without tube feeding (see Supporting Information Table [S2](#eat23037-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#eat23037-sec-0022}
=============

The prevalence rate of ARFID in our tertiary care multidisciplinary center for pediatric feeding problems is 64%. This study shows that the HRQOL of young ARFID patients is decreased on multiple subscales. ARFID patients aged 0--5 years showed a significantly lower HRQOL on the subscales appetite, lungs, stomach, motor functioning, positive mood and liveliness compared to healthy controls, and on the subscales appetite, stomach, motor functioning, and liveliness compared to chronically ill patients. Parents of ARFID patients reported significantly less problem behavior compared to both healthy and chronically ill controls. The HRQOL of ARFID patients 0--5 years receiving tube feeding did not differ compared to those without tube feeding. ARFID patients aged 6--7 had significantly lower scores on the subscales total score, psychosocial health, and school functioning compared to healthy controls. ARFID patients aged 8--10 had a lower school functioning subscale compared to healthy controls.

The prevalence rate of ARFID in our Diagnostic Center for Feeding Problems is higher than described in other studies: 3.2% in a general pediatric population, 1.5% in a pediatric gastroenterology setting, 15% in an adolescent medicine setting, 13.8% in an adolescent medicine eating disorder program (patients 8--18 years), 22.5% in a day program for children and adolescents with eating disorders and comorbid psychopathology (patients 7--17 years), and 5% in another pediatric tertiary care hospital evaluating all patients with eating disorders (mean age 13.7 ± 2.5 years). All studies used the DSM‐5 criteria to determine if patients had ARFID (Eddy et al., [2015](#eat23037-bib-0011){ref-type="ref"}; Fisher et al., [2014](#eat23037-bib-0017){ref-type="ref"}; Kurz et al., [2015](#eat23037-bib-0028){ref-type="ref"}; Nicely, Lane‐Loney, Masciulli, Hollenbeak, & Ornstein, [2014](#eat23037-bib-0032){ref-type="ref"}; Ornstein et al., [2013](#eat23037-bib-0035){ref-type="ref"}). There might be several explanations for the higher prevalence rate of ARFID in our study. The first reason is our specialized tertiary care setting for feeding problems in which patients with severe feeding problems from the whole country are seen as a second or third opinion. In addition, our hospital is known to perform the clinical hunger provocation program to wean children from tube feeding and initiate oral feeding. For this particular reason, tube‐fed children are often referred to our hospital. Then, our patients are younger than those of earlier mentioned studies, and it is known that children with ARFID tend to be younger compared to other eating disorders (Norris et al., [2014](#eat23037-bib-0033){ref-type="ref"}). Furthermore, the fact that our tertiary care center has a large NICU ward, and is an expert center for certain genetic diseases and syndromes contributed to our population consisting of medically fragile children with almost 90% of ARFID patients showing comorbidities. When comparing ARFID patients to other DSM‐5 eating disorders or in various clinical settings, ARFID patients are found to be a heterogeneous group with varying ages and comorbidities. They are more often diagnosed with medical comorbidities/conditions, including but not limited to congenital malformations, very low birth weight, cerebral palsy, and diseases of the gastrointestinal tract that may be related or unrelated to the ARFID diagnosis. They can be tube dependent as well (Eddy et al., [2015](#eat23037-bib-0011){ref-type="ref"}; Fisher et al., [2014](#eat23037-bib-0017){ref-type="ref"}; Norris et al., [2016](#eat23037-bib-0034){ref-type="ref"}). Additionally, the diversity within the ARFID population may be attributed to the chronic medical conditions and/or development delays associated with feeding issues (Bryant‐Waugh, Markham, Kreipe, & Walsh, [2010](#eat23037-bib-0005){ref-type="ref"}; Rommel, de Meyer, Feenstra, & Veereman‐Wauters, [2003](#eat23037-bib-0037){ref-type="ref"}; Wilken et al., [2018](#eat23037-bib-0039){ref-type="ref"}). As such, the DSM‐5 criteria do not exclude patients with the aforementioned comorbidities from the ARFID diagnosis.

Tube feeding or symptoms of the medical condition may have triggered the food aversion and refusal in the beginning (Hartdorff et al., [2015](#eat23037-bib-0019){ref-type="ref"}; Levy et al., [2009](#eat23037-bib-0029){ref-type="ref"}). Therefore, it can be difficult to distinguish between medical conditions and ARFID. However, the diagnosis ARFID can be made if the feeding disturbance is more severe, and therefore warrants additional attention, than which can be expected of the medical condition only, or when the feeding problem does not resolve after treating the medical disorder (American Psychiatric Association & DSM‐5 Task Force, [2013](#eat23037-bib-0001){ref-type="ref"}; Eddy et al., [2015](#eat23037-bib-0011){ref-type="ref"}; Nicely et al., [2014](#eat23037-bib-0032){ref-type="ref"}). Considering the high rate of medical comorbidities in our population of children with ARFID, differences in HRQOL compared to healthy children may also originate from the medical comorbidity, and not just from the feeding problems alone. Therefore, the HRQOL of ARFID patients was compared to chronically ill controls in addition to healthy controls.

The largest age group of our sample consisted of ARFID patients aged 0--5 years old. Their decreased HRQOL subscales appetite and stomach might be explicable both as cause and consequence of the feeding disorder. We believe the impaired HRQOL on the lung subscale, which had a moderate internal consistency, could be better explained by the high rate of respiratory conditions in our population and as a side effect of tube feeding, than by the feeding disorder itself. These children showed a decreased score for the motor functioning and liveliness subscales compared to both healthy and chronically ill children. We hypothesize that this might be due to a lower activity index, associated with a lower energy intake and nutritional status, or due to restriction of movements in tube fed children and less exploration consequently. The severity of feeding problems in this tertiary care sample could have influenced HRQOL. Therefore, these results may not be generalized to the whole pediatric ARFID population. No differences were found on the subscales sleeping, skin, social functioning, communication and anxiety. Especially the latter is remarkable, considering longitudinal studies showing that children with early food refusal were at risk for anxiety disorders (Ammaniti, Lucarelli, Cimino, D\'Olimpio, & Chatoor, [2012](#eat23037-bib-0002){ref-type="ref"}). A possible explanation for this difference could be, that anxiety problems occur later in life. The ARFID patients scored better on the subscale problem behavior (measuring difficult and aggressive behavior of the child with following seven questionnaires roughly translated: "My child was ... (1) bad tempered, (2) aggressive, (3) agitated, (4) angry, (5) impatient, (6) stubborn, (7) unmanageable"), both compared to healthy and chronically ill controls. In contrast to our results, another study revealed infants with feeding problems to show more signs of difficult temperament, heightened emotional reactivity, and aggressive behavior, still present at the age of 5 and 8 years, measured with the child behavior checklist (CBCL 1½--5 and 6--18) (Ammaniti et al., [2012](#eat23037-bib-0002){ref-type="ref"}). On the other hand, another study showed that children who refused to eat at an early age (3--12 months) had more eating problems at home and primary school at follow‐up (9.6 ± 0.3 years), but their general behavior, measured by the total Rutter score and the hyperactivity score calculated from the Rutters\'s "Children\'s behavior questionnaire for completion by teachers" and "Children\'s behavior questionnaire for completion by parents", was not different (Dahl, Rydell, & Sundelin, [1994](#eat23037-bib-0008){ref-type="ref"}). Since the literature is not consistent, problem behavior among children with ARFID needs to be further elucidated in future studies.

Explorative results showed that the children with ARFID aged 6--7 years had lower HRQOL on the total score and on the subscales, psychosocial health, and school functioning, compared to healthy controls, and ARFID patients aged 8--10 had lower HRQOL in the subscale school functioning compared to healthy controls. Prior to the definition ARFID, children with other feeding disorders were also described to have an impaired cognition, show more social and school difficulties, have emotional regulation problems, and show more anxiety and obsessive--compulsive symptoms (Bryant‐Waugh et al., [2010](#eat23037-bib-0005){ref-type="ref"}; Chatoor et al., [2004](#eat23037-bib-0006){ref-type="ref"}; Lukens & Silverman, [2014](#eat23037-bib-0031){ref-type="ref"}; Rommel et al., [2003](#eat23037-bib-0037){ref-type="ref"}). Our explorative results of impaired HRQOL in the older age categories of ARFID patients in addition to the known psychosocial problems in children with other feeding disorders, might indicate that HRQOL in older children could also be impaired, but larger groups are necessary to investigate and confirm this speculation.

In our study approximately 60% of the children were tube fed. In the previous DSM versions, however, these children would probably not have been recognized to have a 'feeding disorder of infancy and early childhood', because they often lack the criteria 'failure to meet appropriate nutritional and/or energy needs'. Patients who do meet appropriate nutritional and/or energy needs, but whom rely on enteral feeding or oral nutritional supplements, may now fulfill the relatively new diagnosis ARFID in contrast to the former DSM‐diagnosis 'feeding disorder of infancy and early childhood' (Bryant‐Waugh et al., [2010](#eat23037-bib-0005){ref-type="ref"}). Studies analyzing the HRQOL in children with feeding disorders other than ARFID receiving tube feeding have scarcely been performed. Davis (2016) measured the HRQOL in tube dependent children at baseline and after treatment to wean children off tube to oral feeding with the Infant Toddler Quality of Life. The HRQOL scores improved significantly on the subscales growth and development, behavior, general health perceptions, parental health: emotional, and parental health: time. They also report the HRQOL to be generally low compared to other studies, but it is unclear how this was measured exactly (Davis et al., [2016](#eat23037-bib-0009){ref-type="ref"}). Dunitz‐Scheer et al. ([2009](#eat23037-bib-0010){ref-type="ref"}) also reported an impaired quality of life, but did not mention if and how the quality of life had been measured. Since tube feeding can impact health and psychosocial functioning in children, we suspected that ARFID patients receiving tube feeding, would also have lower HRQOL subscales (Benoit et al., [2000](#eat23037-bib-0003){ref-type="ref"}; Hartdorff et al., [2015](#eat23037-bib-0019){ref-type="ref"}; Krom et al., [2017](#eat23037-bib-0026){ref-type="ref"}; Krom et al., [2018](#eat23037-bib-0027){ref-type="ref"}; Wilken et al., [2018](#eat23037-bib-0039){ref-type="ref"}). However, no significant differences were found in our study. This might be due to the small patient sample. Further studies assessing the health related quality of life in a larger sample size of tube fed children are necessary.

4.1. Strengths and Limitations {#eat23037-sec-0023}
------------------------------

This is the first study reporting HRQOL in children with ARFID. The high response rate of 75% is the result of several phone calls to remind the parents of the patients to complete the questionnaires, which led to obtaining a relatively large sample. Another strength of the study was the use of validated questionnaires of representative healthy Dutch norm groups (Engelen et al., [2009](#eat23037-bib-0014){ref-type="ref"}; Fekkes et al., [2000](#eat23037-bib-0015){ref-type="ref"}). Considering so many children had medical comorbidities, we compared them with a Dutch reference group of chronically ill children as well.

Some limitations, however, have to be considered. Due to the cross‐sectional design of the study, causality cannot be determined. Questionnaire studies are always at risk for selection bias. This, however, was not objected and likely, as we found no significant differences between participants and nonparticipants. The by proxy questionnaires were also a limitation, since the parental perception of the HRQOL of their child might be influenced by their own mental health and concerns (Eiser & Morse, [2001b](#eat23037-bib-0013){ref-type="ref"}). As the diagnosis ARFID was not used in our clinical setting at the start of the study, the diagnosis was made retrospectively by the research physician. As the reference group of chronically ill children was gathered from a general population, it could be possible that comorbidity of our patients was more severe, which also may have contributed to the lower HRQOL scores of ARFID patients. The small sample size for the PedsQL in both age groups (6--7 and 8--10 years), and a low internal consistency in some of the subscales were limitations of the study.

5. CONCLUSION {#eat23037-sec-0024}
=============

HRQOL of children with ARFID is lower compared to both healthy and chronically ill controls. The subgroup of ARFID patients receiving tube feeding did not differ significantly from those not receiving tube feeding. We recommend to add HRQOL as an outcome measure in clinical studies. Assessing the HRQOL of children with ARFID in daily practice can detect problems on the affected subscales, and personalized care from appropriate disciplines can focus on these problems to improve the HRQOL. Especially the psychologist may play a key role in evaluating and treating psychosocial problems and the HRQOL. Further studies, however, should determine if this will lead to an improvement of HRQOL by measuring the HRQOL in a standardized way before and after treatment. The HRQOL of children with tube feeding should be measured in a larger sample size. Furthermore, the parental HRQOL of children with ARFID compared to healthy and chronically ill children should be measured. Future studies should also assess the behavior and psychopathology of children with ARFID and their parents in order to target treatment, and improve care.
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